CD40 and autoimmune disease: As ICP targets show particular promise (62), SMIPPIs targeting immune costimulation, such as those discussed here (i.e., CD40–CD40L), could ultimately lead to effective immunomodulatory therapeutics for the prevention of T1D and possibly other autoimmune diseases as well.